1. Effect of adapalene 0.1%/benzoyl peroxide 2.5% topical gel on quality of life and treatment adherence during long-term application in patients with predominantly moderate acne with or without concomitant medication - additional results from the non-interventional cohort study ELANG.
- Author
-
Gollnick HP, Friedrich M, Peschen M, Pettker R, Pier A, Streit V, Jöstingmeyer P, Porombka D, Rojo Pulido I, and Jäckel A
- Subjects
- Acne Vulgaris psychology, Adapalene administration & dosage, Administration, Cutaneous, Adolescent, Adult, Aged, Anti-Bacterial Agents therapeutic use, Benzoyl Peroxide administration & dosage, Child, Drug Combinations, Drug Therapy, Combination, Facial Dermatoses psychology, Female, Gels, Humans, Male, Middle Aged, Patient Satisfaction, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Time Factors, Young Adult, Acne Vulgaris drug therapy, Adapalene therapeutic use, Benzoyl Peroxide therapeutic use, Facial Dermatoses drug therapy, Medication Adherence statistics & numerical data, Quality of Life psychology
- Abstract
Background: In addition to physical long-lasting effects such as permanent scarring and disfigurement, acne has acute and long-term psychosocial effects that affect the individual's quality of life. As with other chronic diseases, treatment success is often compromised by poor adherence., Objective: Two main objectives of this non-interventional study were to assess the long-term effect of the fixed-dose combination adapalene 0.1%/benzoyl peroxide 2.5% (adapalene-BPO gel) on quality of life and treatment adherence., Methods: Patients with moderate to severe facial acne receiving adapalene-BPO alone or in combination with other drugs were enrolled in this non-interventional study. Data were documented at baseline and after 3 and 9 months of adapalene-BPO treatment. The secondary outcomes reported here include quality of life determined by the Cardiff Acne Disability Index (CADI), treatment adherence assessed by the ECOB (Elaboration d'un outil d'evaluation de l'observance des traitements medicamenteux) questionnaire, and patient satisfaction., Results: In total, 5131 patients were included in the efficacy evaluation. After 9 months, mean (±SD) quality of life (CADI) improved significantly from 5.9 ± 3.0 to 2.4 ± 2.7 (P < 0.0001). Patients with more severe acne at baseline tended to achieve a greater improvement in quality of life. Long-term adherence was found to be good in 83.9% of patients. Adherence had a significant effect on efficacy and quality of life (P < 0.0001 respectively). The vast majority of patients (92.1%) reported subjective improvement at the interim analysis. Accordingly, most patients (84.8%) were satisfied or very satisfied with adapalene-BPO by the end of the observation period., Conclusion: The clinical improvement of the disease led to an increase in quality of life among acne patients. The treatment success may be a motivation factor for patients to stay adherent over the long-term treatment course, indicating the qualification of adapalene-BPO topical gel as an appropriate medication also in the long-term usage., (© 2015 European Academy of Dermatology and Venereology.)
- Published
- 2015
- Full Text
- View/download PDF